SHR-1222
Phase 1Small molecule
SHR-1222 is one of 37 small molecule programs targeting Postmenopausal Osteoporosis. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Postmenopausal Osteoporosis
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Evista
Eli LillyApproved
Forteo
AAlmaject
Approved
Calciferol
Alnylam PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Boniva
CConrado Roberto Hoffmann Filho
Approved
Estradiol Valerate
BayerApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postmenopausal Osteoporosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-1222. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details